Autopsy report · NCT06033833
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Cause of deathFunding or business
“Sponsor decision; the decision is not related to any safety concern.”
Life of this trial
- Ran for about 3 years 1 month before it stopped.
- 335 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Conditions
- Asthma
- Interventions
- Amlitelimab; Placebo
- Participants
- 335
- Sites
- 68
- Countries
- Argentina, Brazil, Canada, Chile, Hungary, Italy, Japan, Mexico, Poland, South Africa, South Korea, Turkey (Türkiye) and more
Trials that died the same way
- REGENETEN™ Bioinductive Implant System in Full-thickness Tears
“Sponsor decision not related to safety.” - Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
“Sponsor decision not related to safety concerns” - Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
“This was a sponsor decision and was not a consequence of any safety concern” - Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
“Sponsor decision not related to safety reasons” - Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
“Sponsor decision, not for safety reasons.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.